Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy.
BACKGROUND
Correlation between p53 autoantibodies (p53 Abs) titers and the efficacy of Taiwanese lung cancer patients undergoing chemotherapy has never been investigated. Our present study aimed at evaluating putative possibility of using p53 Abs levels as a model system to monitor effect of chemotherapy and prognosis prediction of lung cancer.


METHODS
The prevalence of p53 Abs in lung cancer patients and temporal alteration of p53 Abs titers in lung cancer patients carrying p53 Abs were investigated by using ELISA and Western blot analysis.


RESULTS
p53 Abs was detected in 17 of 277 (6.14%) lung cancer patients, the positivity of p53 Abs in patients with small cell lung carcinoma and non-small cell lung carcinoma was 4.88% and 6.36%, respectively. No significant association between p53 Abs and patients' clinical manifestations was found. Titer of p53 Abs was decreased in 6 of 17 p53 Abs-carrying patients after chemotherapy. However, the decreasing p53 Abs titers were not correlated with patients' survival or chemotherapeutic efficacy.


CONCLUSIONS
The prevalence of p53 Abs in Taiwanese lung cancer is much lower than that in Caucasians. It is unlikely that p53 Abs titer could be a monitoring indicator for the chemotherapeutic efficacy or a prognosis indicator of lung cancer.
Lee
Yao-Ling
YL
School of Medical Technology, Chung Shan Medical University, Taichung 402, Taiwan, Republic of China.
Shih
Chuen-Ming
CM
Chiou
Hui-Ling
HL
Shiau
Ming-Yuh
MY
Chang
Gee-Chen
GC
Chang
Yih-Hsin
YH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000032:analysis*; D015153:Blotting, Western; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013624:Taiwan; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology*
D000970:Antineoplastic Agents; D001323:Autoantibodies; D018076:DNA, Complementary; D016159:Tumor Suppressor Protein p53